ACADIA PHARMACEUTICALS INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for ACADIA PHARMACEUTICALS INC (ACAD), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ACAD insiders buying or selling?
In the last 12 months, ACADIA PHARMACEUTICALS INC insiders reported 0 open-market purchases ($0) and 17 sales ($3.4M) — net selling of $3.4M. Since January 2018, Trabud has recorded 164 Form 4 filings for ACAD: 6 buys ($341.7M) and 158 sells ($78.9M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Aug 7, 2026)
Total Form 4 filings
164
SEC EDGAR
Insider filers
18
Insider buys (6)
$341.7M
Insider sells (158)
$78.9M
Insider sentiment
Net buyingNet insider flow of $262.8M in net buying since January 2018, and $3.4M in net selling over the last 12 months.
Recent ACAD insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 20.1K | $29.16 | $587.2K | SEC ↗ |
| Jul 31, 2026 | Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | Sale | 16.6K | $26.13 | $432.7K | SEC ↗ |
| Jun 29, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 11.4K | $26.08 | $297.9K | SEC ↗ |
| May 27, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 5.4K | $21.18 | $114.4K | SEC ↗ |
| May 5, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.3K | $21.79 | $29.0K | SEC ↗ |
| May 5, 2026 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 3.5K | $21.79 | $76.4K | SEC ↗ |
| Apr 7, 2026 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 2.7K | $22.20 | $60.1K | SEC ↗ |
| Apr 7, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.0K | $22.20 | $22.9K | SEC ↗ |
| Mar 27, 2026 | Adams Catherine Owen | Chief Executive Officer | Sale | 11.6K | $21.47 | $249.9K | SEC ↗ |
| Mar 27, 2026 | Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | Sale | 3.8K | $21.47 | $82.5K | SEC ↗ |
| Mar 27, 2026 | Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | Sale | 3.4K | $21.47 | $73.7K | SEC ↗ |
| Mar 27, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.9K | $21.57 | $41.9K | SEC ↗ |
| Mar 27, 2026 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 7.4K | $21.55 | $159.1K | SEC ↗ |
| Feb 10, 2026 | Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | Sale | 7.0K | $23.38 | $162.5K | SEC ↗ |
| Nov 19, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 10.3K | $23.69 | $243.1K | SEC ↗ |
| Nov 19, 2025 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 4.1K | $23.69 | $96.8K | SEC ↗ |
| Nov 12, 2025 | James M Daly | Director | Sale | 30.0K | $22.37 | $671.0K | SEC ↗ |
| Sep 16, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 3.5K | $23.65 | $82.7K | SEC ↗ |
| Sep 3, 2025 | Elizabeth A. Garofalo | Director | Sale | 1.6K | $25.98 | $41.6K | SEC ↗ |
| Aug 19, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 22.0K | $25.18 | $554.0K | SEC ↗ |
| Jun 5, 2025 | Laura Brege | Director | Sale | 14.4K | $21.78 | $314.6K | SEC ↗ |
| May 20, 2025 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 4.0K | $22.50 | $90.0K | SEC ↗ |
| May 20, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 2.0K | $25.00 | $50.0K | SEC ↗ |
| May 3, 2025 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.3K | $14.60 | $19.4K | SEC ↗ |
| May 2, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 3.5K | $14.60 | $51.1K | SEC ↗ |
Showing the 25 most recent of 164 Form 4 filings for ACADIA PHARMACEUTICALS INC.
Most active ACAD insiders
- Mark C. Schneyer27 filings
- James Kihara25 filings
- Stephen Davis25 filings
- Srdjan R. Stankovic18 filings
- Brendan Teehan16 filings
Ask anything about ACAD insider activity
Use Trabud's AI agent to query ACADIA PHARMACEUTICALS INC's Form 4 history in plain English — "Show me ACAD CEO purchases this year" or compare it against any other ticker.
Open the AI agentACAD insider trading FAQ
Are ACADIA PHARMACEUTICALS INC insiders buying or selling?
In the last 12 months, ACADIA PHARMACEUTICALS INC insiders reported 0 open-market purchases ($0) and 17 sales ($3.4M) — net selling of $3.4M. Since January 2018, Trabud has recorded 164 Form 4 filings for ACAD: 6 buys ($341.7M) and 158 sells ($78.9M). Over the full record that is net buying of $262.8M.
How many insiders trade ACAD stock?
18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for ACADIA PHARMACEUTICALS INC. The most recent filing was accepted on Aug 7, 2026.
Where does Trabud get ACAD insider trading data?
All ACAD insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.